Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors
- PMID: 24074416
- DOI: 10.1016/j.surg.2013.07.004
Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors
Abstract
Purpose: The biologic potential of nonfunctioning pancreatic neuroendocrine tumors (PNETs) is highly variable and difficult to predict before resection. This study was conducted to identify clinical and pathologic factors associated with malignant behavior and death in patients diagnosed with PNETs.
Methods: We used International Classification of Diseases 9th edition codes to identify patients who underwent pancreatectomy for PNETs from 1998 to 2011 in the databases of 4 institutions. Functioning PNETs were excluded. Multivariate regression Cox proportional models were constructed to identify clinical and pathologic factors associated with distant metastasis and survival.
Results: The study included 128 patients-57 females and 71 males. The age (mean ± standard deviation) was 55 ± 14 years. The body mass index was 28 ± 5 kg/m(2). Eighty-nine (70%) patients presented with symptoms, and 39 (30%) had tumors discovered incidentally. The tumor size was 3.3 ± 2 cm with 56 (44%) of the tumors measuring ≤2 cm. Seventy-three (57%) patients had grade 1 histology tumors, 37 (29%) had grade 2, and 18 (14%) had grade 3. Peripancreatic lymph node involvement was present in 31 patients (24%), absent in 75 (59%), and unknown in 22 (17%). Distant metastasis occurred in 18 patients (14%). There were 12 deaths, including 1 perioperative, 8 disease related, and 3 of unknown cause. With a median follow-up of 33 months, the overall 5-year survival was 75%. Multivariate Cox regression analysis identified age >55 (hazard ratio [HR], 5.89; 95% confidence interval [CI], 1.64-20.58), grade 3 histology (HR, 6.08; 95% CI, 1.32-30.2), and distant metastasis (HR, 8.79; 95% CI, 2.67-28.9) as risk factors associated with death (P < .05). Gender, race, body mass index, clinical symptoms, lymphovascular and perineural invasion, and tumor size were not related to metastasis or survival (P > .05). Three patients with tumors ≤2 cm developed distant metastasis resulting in 2 disease-related deaths.
Conclusion: Age >55 years, grade 3 histology, and distant metastasis predict a greater risk of death from nonfunctioning PNETs. Resection or short-term surveillance should be considered regardless of tumor size.
Copyright © 2013 Mosby, Inc. All rights reserved.
Comment in
-
Comment on "peroral esophageal myotomy (POEM) and laparoscopic Heller myotomy produce a similar short-term anatomic and functional effect".Surgery. 2014 Mar;155(3):582. doi: 10.1016/j.surg.2013.10.023. Epub 2013 Oct 22. Surgery. 2014. PMID: 24462076 No abstract available.
Similar articles
-
Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.Ann Surg Oncol. 2013 Sep;20(9):2815-21. doi: 10.1245/s10434-013-3005-7. Epub 2013 Jun 15. Ann Surg Oncol. 2013. PMID: 23771245
-
Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas.Am Surg. 2000 Dec;66(12):1116-22; discussion 1122-3. Am Surg. 2000. PMID: 11149582
-
Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors.Surgery. 2014 Dec;156(6):1504-10; discussion 1510-1. doi: 10.1016/j.surg.2014.08.043. Epub 2014 Nov 11. Surgery. 2014. PMID: 25456943
-
Pancreatic Surgery.Front Horm Res. 2015;44:139-48. doi: 10.1159/000382143. Epub 2015 Aug 14. Front Horm Res. 2015. PMID: 26303709 Review.
-
Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?Cancer Control. 2008 Oct;15(4):314-21. doi: 10.1177/107327480801500406. Cancer Control. 2008. PMID: 18813199 Review.
Cited by
-
Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.Medicine (Baltimore). 2020 Jun 12;99(24):e20324. doi: 10.1097/MD.0000000000020324. Medicine (Baltimore). 2020. PMID: 32541455 Free PMC article.
-
Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based Study.Front Endocrinol (Lausanne). 2022 Jul 18;13:928341. doi: 10.3389/fendo.2022.928341. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35923628 Free PMC article.
-
Long-term survival after repetitive lymphadenectomy for nodal recurrence of pancreatic neuroendocrine neoplasms: a report of two cases.J Surg Case Rep. 2021 Oct 13;2021(10):rjab446. doi: 10.1093/jscr/rjab446. eCollection 2021 Oct. J Surg Case Rep. 2021. PMID: 34659739 Free PMC article.
-
The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.Surgery. 2019 Jul;166(1):15-21. doi: 10.1016/j.surg.2019.03.008. Epub 2019 May 6. Surgery. 2019. PMID: 31072670 Free PMC article.
-
Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors.J Gastrointest Surg. 2015 Jan;19(1):117-23; discussion 123. doi: 10.1007/s11605-014-2615-0. Epub 2014 Aug 26. J Gastrointest Surg. 2015. PMID: 25155459
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical